Literature DB >> 15113854

Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia.

C Jakubzick1, E S Choi, S L Kunkel, H Evanoff, F J Martinez, R K Puri, K R Flaherty, G B Toews, T V Colby, E A Kazerooni, B H Gross, W D Travis, C M Hogaboam.   

Abstract

BACKGROUND: Some idiopathic interstitial pneumonias (IIPs) are characterised by fibroproliferation and deposition of extracellular matrix. Because efficacious treatment options are limited, research has been directed towards understanding the cytokine networks that may affect fibroblast activation and, hence, the progression of certain IIPs. AIMS: To examine the expression of interleukin 4 (IL-4), IL-13, and their corresponding receptor subunits in the various forms of IIP and normal patient groups.
METHODS: Molecular and immunohistochemical analysis of IL-4, interferon gamma (IFNgamma), IL-13, IL-4 receptor (IL-R), and IL-13 receptor subunits in surgical lung biopsies (SLBs) from 39 patients (21 usual interstitial pneumonia (UIP), six non-specific interstitial pneumonia (NSIP), eight respiratory bronchiolitic interstitial lung disease (RBILD), and five normal controls).
RESULTS: Molecular analysis demonstrated that IL-13Ralpha2, IL-13Ralpha1, and IL-4Ralpha were present in a greater proportion of upper and lower lobe biopsies from patients with UIP than patients with NSIP and RBILD. Immunohistochemical analysis of patients with UIP, NSIP, and RBILD revealed interstitial staining for all three receptor subunits, whereas such staining was only seen in mononuclear cells present in normal SLBs. Fibroblastic foci in patients with UIP strongly stained for IL-4Ralpha and IL-13Ralpha2. Localised expression of IL-4Ralpha was also seen in SLBs from patients with NSIP but not in other groups.
CONCLUSION: Some histological subtypes of IIP are associated with increased pulmonary expression of receptor subunits responsive to IL-4 and IL-13. These findings may be of particular importance in understanding the pathogenesis of IIP and, more importantly, may provide important novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113854      PMCID: PMC1770295          DOI: 10.1136/jcp.2003.012799

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  52 in total

1.  Respiratory bronchiolitis associated with severe dyspnea, exertional hypoxemia, and clubbing.

Authors:  R T Sadikot; J Johnson; J E Loyd; J W Christman
Journal:  Chest       Date:  2000-01       Impact factor: 9.410

2.  Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival.

Authors:  K R Flaherty; G B Toews; J P Lynch; E A Kazerooni; B H Gross; R L Strawderman; K Hariharan; A Flint; F J Martinez
Journal:  Am J Med       Date:  2001-03       Impact factor: 4.965

3.  Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts.

Authors:  A Oriente; N S Fedarko; S E Pacocha; S K Huang; L M Lichtenstein; D M Essayan
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

4.  The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway.

Authors:  K Kawakami; J Taguchi; T Murata; R K Puri
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

5.  Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma.

Authors:  K Blease; C Jakubzick; J Westwick; N Lukacs; S L Kunkel; C M Hogaboam
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

6.  In vitro production of B cell growth factor and B cell differentiation factor by peripheral blood mononuclear cells and bronchoalveolar lavage T lymphocytes from patients with idiopathic pulmonary fibrosis.

Authors:  M Emura; S Nagai; M Takeuchi; M Kitaichi; T Izumi
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

7.  A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.

Authors:  R Ziesche; E Hofbauer; K Wittmann; V Petkov; L H Block
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

8.  Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival.

Authors:  W W Douglas; J H Ryu; D R Schroeder
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

9.  Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies.

Authors:  S Majumdar; D Li; T Ansari; P Pantelidis; C M Black; M Gizycki; R M du Bois; P K Jeffery
Journal:  Eur Respir J       Date:  1999-08       Impact factor: 16.671

Review 10.  Interstitial fibrosis and growth factors.

Authors:  J A Lasky; A R Brody
Journal:  Environ Health Perspect       Date:  2000-08       Impact factor: 9.031

View more
  21 in total

1.  Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopathic interstitial pneumonia.

Authors:  E S Choi; E M Pierce; C Jakubzick; K J Carpenter; S L Kunkel; H Evanoff; F J Martinez; K R Flaherty; B B Moore; G B Toews; T V Colby; E A Kazerooni; B H Gross; W D Travis; C M Hogaboam
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

Review 2.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

3.  HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis.

Authors:  Kemly Philip; Tingting Weng Mills; Jonathan Davies; Ning-Yuan Chen; Harry Karmouty-Quintana; Fayong Luo; Jose G Molina; Javier Amione-Guerra; Neeraj Sinha; Ashrith Guha; Holger K Eltzschig; Michael R Blackburn
Journal:  FASEB J       Date:  2017-07-12       Impact factor: 5.191

4.  γδ T cells attenuate bleomycin-induced fibrosis through the production of CXCL10.

Authors:  Derek A Pociask; Kong Chen; Sun Mi Choi; Tim D Oury; Chad Steele; Jay K Kolls
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

Review 6.  The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Benjamin D Bringardner; Christopher P Baran; Timothy D Eubank; Clay B Marsh
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

Review 7.  Pulmonary fibrosis: pathogenesis, etiology and regulation.

Authors:  M S Wilson; T A Wynn
Journal:  Mucosal Immunol       Date:  2009-01-07       Impact factor: 7.313

8.  TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation.

Authors:  A Meneghin; E S Choi; H L Evanoff; S L Kunkel; F J Martinez; K R Flaherty; G B Toews; C M Hogaboam
Journal:  Histochem Cell Biol       Date:  2008-07-17       Impact factor: 4.304

9.  Interleukin-13 disrupts type 2 pneumocyte stem cell activity.

Authors:  Kristen M Glisinski; Adam J Schlobohm; Sarah V Paramore; Anastasiya Birukova; M Arthur Moseley; Matthew W Foster; Christina E Barkauskas
Journal:  JCI Insight       Date:  2020-01-16

10.  Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function.

Authors:  Sung-Woo Park; Mi-Hyun Ahn; Hee Kyung Jang; An Soo Jang; Do-Jin Kim; Eun-Suk Koh; Jong-Sook Park; Soo-Taek Uh; Yong Hoon Kim; Jai Soung Park; Sang Hyun Paik; Hwa-Kyun Shin; Wook Youm; Choon-Sik Park
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.